Role of FDG PET/CT in the Evaluation of Therapy Response in Systemic Juvenile Xanthogranuloma

Abstract

Juvenile xanthogranuloma, a rare type of non-Langerhans cell histiocytosis, is mostly seen in childhood and adolescence and generally manifests as widespread skin lesions. It rarely shows systemic involvement. Although the cutaneous form is often self-limited, systemic form is quite aggressive. Here we report the findings of FDG PET/CT scans during the course of cladribine therapy in a 6-year-old girl with systemic juvenile xanthogranuloma.

The Impact of PET/CT on Paediatric Oncology

“…Extracutaneous manifestations confer it a poor prognosis with a mortality rate of 5-10 %; 2-[ 18 F]FDG can assist stratifying extent of disease, despite there being no clear consensus recommendations on the preferred modality for monitoring therapy. Limited case reports have shown the utility of FDG to assist in staging and response assessment to therapy in multiple cutaneous and extracutaneous sites [90,91].…”